BCG 006
Alternative Names: BCG-006Latest Information Update: 24 Apr 2023
Price :
$50 *
At a glance
- Originator Beijing Biocytogen
- Developer Beijing Biocytogen; Undisclosed
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 14 Apr 2023 Early research in Cancer in China (Parenteral) before April 2023 (Beijing Biocytogen pipeline, April 2023)